Safety and Pharmacokinetics of GEH200486 in Healthy Volunteers

Pharmacokinetics Clinical Trial

Official title:

A Phase 1 Single Centre, Single Ascending Dose Safety Study of GEH200486 in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05569278
• Other study ID #: GE-227-001
• Secondary ID: 2021-005791-19
• Status: Completed
• Phase: Phase 1
• Start date: August 22, 2022
• Est. completion date: November 29, 2022

Study information

• Verified date: July 2023
• Source: GE Healthcare
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single center, prospective, dose escalation study (4 different dose levels) for a novel magnetic resonance imaging (MRI) contrast agent, in male and female healthy volunteers . The study is primarily designed to collect safety data. In addition, researchers want to learn more about how the novel contrast agent, GEH200486 circulates and is eliminated from the body (pharmacokinetics) after injection in healthy volunteers. Up to 24 healthy volunteers will be enrolled and will each receive a single administration of one of the 4 doses of GEH200486. Each healthy volunteer will stay at the clinical unit for the first 24 hours post injection and return for up to 3 follow-up visits with 1 additional follow-up phone call.

Dose escalation from one dose group to the next dose group will be sequential and only be allowed if the clinical safety of all healthy volunteers from the tested dose group is acceptable, as assessed by an independent safety committee, members of GEHC team and the principal investigator.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: November 29, 2022
• Est. primary completion date: November 29, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• The subject is between 18 to 55 years of age

• The subject has no currently active significant medical illness or history of chronic medical illness.

• The subject has no clinically significant deviation from normal ranges in physical examination, ECG, and clinical laboratory parameters.

• The subject has read, signed, and dated an informed consent form (ICF) prior to any study procedures being performed, and is willing to allow the study Investigator to make the subject's medical records available to GE Healthcare

• The subject is able and willing to comply with all study procedures as described in the protocol.

• Female subjects: The subject is a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (amenorrhoea duration of at least 12 consecutive months), or non- lactating, or if of childbearing potential the results of a urine human chorionic gonadotropin pregnancy test, performed at screening and on the day of dosing, prior to administration (with the result known before investigational medicinal product [IMP] administration), must be negative. Women of childbearing potential must use adequate contraception from screening until 30 days after administration of IMP. Such methods include: hormonal contraception including oral contraceptives; intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion; vasectomised partner; sexual abstinence.

• Male subjects: The subject is a male who is either surgically sterile or males who are sexually active with a partner of childbearing potential must use adequate contraception from screening until 30 days after administration of IMP. Such methods include: vasectomy; sexual abstinence. Male subjects must agree not to donate sperm from screening through 30 days after administration of IMP

Exclusion Criteria:

• Subjects who are unable to undergo any of the study procedures.

• Subjects with any significant currently active or chronic medical illness (e.g., cardiovascular disease, renal impairment, hepatic dysfunction, Parkinson's disease) or recent significant trauma (e.g., motor vehicle accident) or any condition that may have disrupted and/or increased permeability of the blood-brain barrier.

• Subjects with any major surgery within 4 weeks prior to enrolment or planned within 2 weeks after completion of the study.

• Subjects who have a positive urine screen for alcohol and/or recreational drugs at screening or before dosing.

• Subjects who are taking prescribed medication (other than contraception) within 2 weeks prior to enrolment or anticipate using prescribed medication (other than oral contraception) during the enrolment period through study follow-up. Limited use of non- prescription medications which in the Investigator's opinion will not affect subject safety or the overall results of the study may be permitted (e.g., acetaminophen/paracetamol) on a case-by-case basis following approval by the Sponsor.

• Subjects who have undergone a contrast-enhanced (CE) imaging procedure (CE-MRI, CE computed tomography [CT]) during the 30 days prior to dosing.

• Subjects who are taking any concomitant medications or dietary supplements that are known to increase blood levels of Mn, Zn, copper (Cu), or iron (Fe) for the duration of the study.

• Subjects who have serious allergic history or known or suspected allergy to the study drug GEH200486 0.5 M Injection or study drug ingredients.

• Subjects who present with any clinically active, serious, life-threatening disease, medical or psychiatric condition, known abuse or misuse of prescription or non-prescription drugs and subjects whom the Investigator judges to be unsuitable for participation in the study for any reason.

• Subjects with previous (within 30 days before administration of IMP or within 5 half-lives of the investigational treatment of the previous study, whichever is longer) or concomitant participation in another clinical study with IMP(s).

Related Conditions & MeSH terms

• Pharmacokinetics

Intervention

Drug:
• GE200486 0.5M Injection
Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush

Locations

Country	Name	City	State
Norway	Rikshospitalet	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
GE Healthcare

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Collection of occurrence of IMP-related SAEs		After administration of IMP until 72 hours post dose (up to 17 days post dose)
Primary	Collection of TEAEs		After administration of IMP until 72 hours post dose (up to 17 days post dose)
Primary	Collection of AEs		After administration of IMP until 72 hours post dose (up to 17 days post dose)
Primary	Injection site monitoring findings at pre-specified time points.		Continuous monitoring from IMP injection up to 24 hours
Primary	Change from baseline in the results of serum biochemistry test results at pre-specified time points.	In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.	Baseline, 1 hour, 4 hours, 24 hours, 48 hours and 72 hours post IMP administration
Primary	Change from baseline in the results of urinalysis at pre-specified time points.	In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.	Baseline, 48 hours and 72 hours post IMP administration
Primary	Change from baseline in the results of haematology at pre-specified time points.	In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.	Baseline, 1 hour, 4 hours, 24 hours, 48 hours and 72 hours post IMP administration
Primary	Measure of blood pressure in mmHg at pre-specified time points		Baseline, 10 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, 48 hours and 72 hours post IMP administration
Primary	Measure of body temperature as degree C at pre-specified time points		Baseline, 10 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, 48 hours and 72 hours post IMP administration
Primary	Measure of heart rate as bpm at pre-specified time points		Baseline, 10 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, 48 hours and 72 hours post IMP administration.
Primary	Measure of respiratory rate per min at pre-specified time points		Baseline, 10 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, 48 hours and 72 hours post IMP administration
Secondary	Pharmacokinetic assessment	AUC0-t Area under the concentration versus time curve (AUC) from time zero to the last measurable concentration, calculated using the linear up/log down trapezoidal rule.	pre-dose to 24 hours
Secondary	Change from baseline in the results of ECG examinations (PR interval, QTc, QRS and RR interval) at pre-specified time points.		Baseline (prior to IMP administration) up to 72 hours